STOCK TITAN
  1. Home
  2. Sec-filings
  3. CAI
  4. [Form 4] Caris Life Sciences, Inc. Insider Trading Activity

Caris Life Sciences (CAI) CFO reports option exercises and stock sales

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Caris Life Sciences, Inc. reported insider transactions by a Senior Vice President, Chief Financial Officer, and Chief Accounting Officer on 12/11/2025. The officer exercised stock options to acquire 24,750 and 37,500 shares of common stock at an exercise price of $2.44 per share.

On the same date, the officer sold 60,850 shares at a weighted average price of $26.5644 and 1,400 shares at a weighted average price of $27.1554, in multiple transactions within stated price ranges. These option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. Following the transactions, the officer directly owns 99,571 shares of Caris Life Sciences common stock, and the reported stock options have been fully exercised.

Positive

  • None.

Negative

  • None.
Insider Power Luke Thomas
Role See Remarks
Sold 62,250 shs ($1.65M)
Type Security Shares Price Value
Exercise Stock Option 24,750 $0.00 --
Exercise Stock Option 37,500 $0.00 --
Exercise Common Stock 24,750 $2.44 $60K
Exercise Common Stock 37,500 $2.44 $92K
Sale Common Stock 60,850 $26.5644 $1.62M
Sale Common Stock 1,400 $27.1554 $38K
Holdings After Transaction: Stock Option — 0 shares (Direct); Common Stock — 124,321 shares (Direct)
Footnotes (1)
  1. The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is fully vested and exercisable.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Power Luke Thomas
(Last) (First) (Middle)
C/O CARIS LIFE SCIENCES, INC.
750 W. JOHN CARPENTER FREEWAY, SUITE 800
(Street)
IRVING TX 75039
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/11/2025 M(1) 24,750 A $2.44 124,321 D
Common Stock 12/11/2025 M(1) 37,500 A $2.44 161,821 D
Common Stock 12/11/2025 S(1) 60,850 D $26.5644(2) 100,971 D
Common Stock 12/11/2025 S(1) 1,400 D $27.1554(3) 99,571 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $2.44 12/11/2025 M(1) 24,750 (4) 05/30/2027 Common Stock 24,750 $0 0 D
Stock Option $2.44 12/11/2025 M(1) 37,500 (4) 11/14/2028 Common Stock 37,500 $0 0 D
Explanation of Responses:
1. The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The stock option is fully vested and exercisable.
Remarks:
Senior Vice President, Chief Financial Officer, and Chief Accounting Officer
/s/ J. Russel Denton, Attorney-in-Fact 12/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Caris Life Sciences (CAI) report in this Form 4?

The filing reports that a Senior Vice President, Chief Financial Officer, and Chief Accounting Officer of Caris Life Sciences, Inc. exercised stock options and sold common shares on 12/11/2025.

How many Caris Life Sciences (CAI) stock options were exercised and at what price?

The officer exercised options covering 24,750 and 37,500 shares of common stock, each with an exercise price of $2.44 per share. The related stock options are reported as fully exercised with 0 derivative securities remaining.

How many Caris Life Sciences (CAI) shares were sold and at what prices?

The officer sold 60,850 shares at a weighted average price of $26.5644, with prices ranging from $26.11 to $27.07, and 1,400 shares at a weighted average price of $27.1554, with prices ranging from $27.11 to $27.20.

What is the remaining Caris Life Sciences (CAI) share ownership after these transactions?

After the reported option exercises and share sales, the officer directly owns 99,571 shares of Caris Life Sciences common stock.

Were the Caris Life Sciences (CAI) insider transactions under a Rule 10b5-1 plan?

Yes. The option exercises and sales were effected under a Rule 10b5-1 trading plan that the reporting person adopted on August 19, 2025.

What do the weighted average prices in the Caris Life Sciences (CAI) Form 4 mean?

The reported prices of $26.5644 and $27.1554 are weighted average prices for multiple trades within stated ranges. The officer has agreed to provide detailed trade-by-trade pricing information upon request.